These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30305587)

  • 1. Sildenafil Reduces the Risk of Thromboembolic Events in HeartMate II Patients with Low-Level Hemolysis and Significantly Improves the Pulmonary Circulation.
    Zayat R; Ahmad U; Stoppe C; Khattab MA; Arab F; Moza A; Tewarie L; Goetzenich A; Autschbach R; Schnoering H
    Int Heart J; 2018 Nov; 59(6):1227-1236. PubMed ID: 30305587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil Is Associated With Reduced Device Thrombosis and Ischemic Stroke Despite Low-Level Hemolysis on Heart Mate II Support.
    Saeed O; Rangasamy S; Selevany I; Madan S; Fertel J; Eisenberg R; Aljoudi M; Patel SR; Shin J; Sims DB; Reyes Gil M; Goldstein DJ; Slepian MJ; Billett HH; Jorde UP
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29092891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are elevated serum haemolysis markers a harbinger of adverse events in HeartMate II patients?
    Zayat R; Shoaib M; Khattab MA; Ahmad U; Goetzenich A; Stoppe C; Foldenauer AC; Moza A; Schnoering H; Autschbach R; Tewarie L
    Interact Cardiovasc Thorac Surg; 2018 Jul; 27(1):5-12. PubMed ID: 29444250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices.
    Birschmann I; Dittrich M; Eller T; Wiegmann B; Reininger AJ; Budde U; Strüber M
    J Heart Lung Transplant; 2014 Jan; 33(1):80-7. PubMed ID: 24418734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to Letter Regarding Article "Sildenafil Reduces the Risk of Thromboembolic Events in HeartMate II Patients with Low-Level Hemolysis and Significantly Improves the Pulmonary Circulation".
    Zayat R; Ahmad U; Autschbach R; Moza A
    Int Heart J; 2019 Jul; 60(4):1015-1016. PubMed ID: 31257343
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter by Nitta, et al. Regarding Article, "Sildenafil Reduces the Risk of Thromboembolic Events in HeartMate II Patients with Low-Level Hemolysis and Significantly Improves the Pulmonary Circulation".
    Nitta D; Imamura T
    Int Heart J; 2019 Jul; 60(4):1013-1014. PubMed ID: 31257339
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival of HeartMate II Patients Despite Cessation of Anticoagulation　- Outcomes and Hemostatic Analysis.
    Zayat R; Khattab MA; Grottke O; Honickel M; Goetzenich A; Moza A; Stoppe C; Autschbach R; Tewarie L
    Circ J; 2018 Apr; 82(5):1309-1318. PubMed ID: 29237991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
    Bansal A; Uriel N; Colombo PC; Narisetty K; Long JW; Bhimaraj A; Cleveland JC; Goldstein DJ; Stulak JM; Najjar SS; Lanfear DE; Adler ED; Dembitsky WP; Somo SI; Crandall DL; Chen D; Connors JM; Mehra MR
    J Heart Lung Transplant; 2019 Aug; 38(8):806-816. PubMed ID: 31147187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events.
    Salerno CT; Sundareswaran KS; Schleeter TP; Moanie SL; Farrar DJ; Walsh MN
    J Heart Lung Transplant; 2014 Aug; 33(8):809-15. PubMed ID: 24735680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study.
    Thenappan T; Stulak JM; Agarwal R; Maltais S; Shah P; Eckman P; Emani S; Katz JN; Gregoric I; Keebler ME; Uriel N; Adler E; Chuang J; Farrar DJ; Sundareswaran KS; John R
    J Heart Lung Transplant; 2018 Jan; 37(1):25-32. PubMed ID: 29153636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant.
    Cowger JA; Romano MA; Shah P; Shah N; Mehta V; Haft JW; Aaronson KD; Pagani FD
    J Heart Lung Transplant; 2014 Jan; 33(1):35-43. PubMed ID: 24418732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
    Uriel N; Colombo PC; Cleveland JC; Long JW; Salerno C; Goldstein DJ; Patel CB; Ewald GA; Tatooles AJ; Silvestry SC; John R; Caldeira C; Jeevanandam V; Boyle AJ; Sundareswaran KS; Sood P; Mehra MR
    Circulation; 2017 May; 135(21):2003-2012. PubMed ID: 28385948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device.
    Stulak JM; Lee D; Haft JW; Romano MA; Cowger JA; Park SJ; Aaronson KD; Pagani FD
    J Heart Lung Transplant; 2014 Jan; 33(1):60-4. PubMed ID: 24021944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients.
    Boyle AJ; Jorde UP; Sun B; Park SJ; Milano CA; Frazier OH; Sundareswaran KS; Farrar DJ; Russell SD;
    J Am Coll Cardiol; 2014 Mar; 63(9):880-8. PubMed ID: 24316083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early postoperative heparinization reduce hemolysis in patients with HeartMate II devices.
    Matsumoto Y; Fukushima S; Shimahara Y; Kawamoto N; Tadokoro N; Kuroda K; Nakajima S; Watanabe T; Seguchi O; Yanase M; Fukushima N; Shimizu H; Kobayashi J; Fujita T
    J Artif Organs; 2020 Mar; 23(1):19-26. PubMed ID: 31482437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
    Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
    Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor.
    Hamdan R; Mansour H; Nassar P; Saab M
    Artif Organs; 2014 Nov; 38(11):963-7. PubMed ID: 24689700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation.
    Stulak JM; Deo S; Schirger J; Aaronson KD; Park SJ; Joyce LD; Daly RC; Pagani FD
    Ann Thorac Surg; 2013 Dec; 96(6):2161-7. PubMed ID: 24035302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.